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Abstract
Some reports have shown the association between Moyamoya syndrome and 
autoimmune diseases. Herewith, we present a 3.5 yr old girl with Henoch-
Schönleinpurpura (HSP) who was treated with steroids because of sever 
colicky abdominal pain. However, central nervous system manifestations such 
as headache, ataxia and vision impairment developed during 6 months of her 
outpatient follow-up. More evaluation using MRA revealed intracranial stenosis 
of internal carotid artery and arterial collaterals that were in favor of Moyamoya 
syndrome. To our knowledge, this is the first report of Moyamoya syndrome 
following henoch-schönleinpurpura.
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Introduction
Moyamoya is known as a disease with unknown pathogenesis presenting with small 
collateral vessels distal to the blockage in the brain blood circulation ( 1). Moyamoya 
is mostly presenting by progressive stenosis of the terminal part of the internal carotid 
artery and its main branches ( 2,  3). The condition can be solely found in the brain 
vasculature, known as moyamoya disease (MMD) or in association with systemic 
disorders, which is moyamoya syndrome (MMS) ( 4). HenochSchonleinpurpura 
(HSP) is the most common vasculitis during childhood that involves small vessels 
in the skin (5). 
The major clinical manifestations of HSP are purpuraor petechiae, abdominal pain, 
arthritis or arthralgia and renal involvement (5-7). The annual incidence of HSP is 
different in various countries and falls in the range of 6.1 to 70.3 per 105 children (5, 
6, 8). HSP usually is a self-limited disease, which has a good prognosis especially 
when the significant renal involvement is absent (8). The etiology of HSP is not clearly 
identified. Infections, vaccination, drugs and insect bite are considered as triggers of 
HSP (6-9). Although the pathogenesis of HSP is not clear, immunoglobulin A (Ig 
A) have a strong role in the pathogenesis of this disease (8, 10).
Rarely HSP patients present signs of CNS or peripheral nervous system dysfunction 
( 5, 11). Neurologic signs and symptoms can be reversible and/or irreversible and 
central  nervous  system  involvement  is reported  in  1%–8%  of  children  and  are 
due to hypertension, renal failure or vasculitis ( 11, 12).
There are some reports showing the association between the moyamoya syndrome 
and autoimmune disorders such as Behcet’s disease, Sjögren’s syndrome, systemic 
lupus erythematosus and Graves disease (13). However, we could not find 
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carotid artery stenosis and diagnostic moyamoya view 
made by the small collateral vessels in the brain imaging 
defining the third grade of moyamoya according to 
Suzuki angiographic classification grades (Figure 1). 
The patient did not go under any brain surgery but was 
ordered to take oral antiplatelet (aspirin) daily however 
she has been suffering from intermittent headaches 
while on medication, as it is mentioned in the literature 
that moyamoya subsequent headache is refractory to 
the medical therapies ( 13). She has been under medical 
supervision for a period of more than 2 years up to now 
as outpatient follow-up.
Discussion
Moyamoya is an abnormal condition of cerebral 
arteries, mostly seen in Asia ( 15) and occurs in women 
twice as in men ( 16). Some genes are introduced to 
cause the disease but presenting the disease in only 
one of the identical twins strongly suggests the role of 
environmental factors in developing the syndrome ( 17). 
Although the exact process leading to moyamoya is still 
unknown but some probable conditions are most likely. 
MMS like cephalic or neck irradiation, skull base tumor, 
atherosclerosis of skull base arteries, chronic meningitis 
(especially tuberculosis meningitis), cerebral vasculitis, 
autoimmune angiitis, prothrombotic disorders and sickle 
cell disease ( 13). 
In this article, we reported a 3.5 yr old Iranian girl who 
showed cerebral signs of moyamoya secondary to her 
inactive HSP. The time interval between primary disease 
and developing CNS complications is in a range from 
one week to 10 yr in the reported cases of systemic lupus 
erythematosus ( 13). In our case, there was 6 months 
interval between presentation of HSP and subsequent 
MMS. Natural history in MMS patients differs greatly 
and can be in a range with slowly progression or rapid 
progression with fulminant manifestations ( 19). The 
signs also depend on the vascular involvement pattern 
and area of the brain affected, but headache is one of 
the frequent complications, which has the quality like 
the migraine headaches ( 13). Vision impairment is also 
another complaint ( 20) which together with previous 
one was presented clearly in our patient.
None of the treatment protocols is able to postpone the 
process of the disease to its primary form and the plans 
Moyamoya syndrome associated with HSP. 
Here with, we present a 3.5 yr old Iranian girl diagnosed 
as having HSP and her fallow up showed the CNS 
involvement signs, an association with Moyamoya 
syndrome which has not been reported up to date.
Case report
In July 2013, a 3.5 yr old girl with history of 
gastroenteritis from 2 weeks earlier was taken to Mofid 
Children Hospital, Tehran, Iran, presenting with petechia 
and purpura on the lower limbs and buttock, ecchymosis 
on the right ear, edema in ankles, right wrist and right 
elbow, arthralgia and abdominal pain. She had neither 
any specific sign of respiratory or urinary tract infection, 
palpable lymphadenopathy nor any known underlying 
disease with similar manifestations. She had a surgery to 
treat her PDA one year ago. 
Informed consent was taken for the patient’s parents.
Due to the severe alternating abdominal pain, the patient 
was admitted to the ward and after physical examinations 
the routine and specific diagnostic laboratory tests were 
done and the results are as followings: White blood cells: 
8110/mm3, platelet: 493000/mm3, hemoglobin: 11 g/
dL, C3: 114mg/dL (90-180), C4: 27.3mg/dL (10-40), 
CH50: 116% (51%-150%), A.N.A  titer<1/40 (normal), 
C-reactive protein level: 27 mg/L (<10), Cr: 0.6 mg/dl, 
BUN: 12mmol/L. Liver function tests including SGOT 
and SGPT were within normal limits. Antistreptolysin 
O titer and throat culture for Streptococcus pyogenes 
(Group A β-hemolytic Streptococcus) were negative 
and urine analysis did not show any abnormal findings. 
Based on the examinations done by the medical staff 
the patient was finally diagnosed as having HSP. She 
was treated by steroid because of persistent colicky 
abdominal pain that dramatically responded. Finally, she 
discharged after complete recuperation.
The patient was visited for 2, 4, and 6 weeks after 
discharging from hospital at the outpatient clinic. 
Her laboratory tests were normal but she expressed 
symptoms of headache during this period of follow-up. 
Almost 4.5 month after discharging, she complicated by 
blurred vision and ataxia beside the headache she had. 
Admitting to the Children Medical Center, magnetic 
resonance angiography (MRA) was done to evaluate 
her CNS manifestations. The MRA showed internal 
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In conclusion, here we described the association between 
autoimmune diseases and moyamoya syndrome and 
presented a case who developed MMS with inactive 
HSP after 6 months of the primary disease onset.
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are mostly to prevent catastrophic complications such 
as stroke ( 21). The long-term medical treatment mainly 
consists of aspirin to make the blood circulation better to 
the compromised areas of the brain ( 22). Some different 
surgical procedures are also used to help the patient with 
revascularization but the treatment plan mostly depends 
on the patient age and the process of the disease ( 23).
Although there is not a definite plan to screen the people 
to find MMD cases but it is suggested to use diagnostic 
MRA to evaluate the patients presenting cerebral signs 
specially with an either active or inactive autoimmune 
disorder, positive family history of MMD in first degree 
relatives and other reported conditions such as Down’s 
syndrome or sickle cell anemia. 
Fig 1. MRA image in sagittal projection (A and B) reveals stenosis of 
distal internal carotid arteries associated with collateral vessel formation
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